HYUNDAI FEED Inc (016790) - Total Liabilities

Latest as of June 2025: ₩28.17 Billion KRW ≈ $19.09 Million USD

Based on the latest financial reports, HYUNDAI FEED Inc (016790) has total liabilities worth ₩28.17 Billion KRW (≈ $19.09 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 016790 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

HYUNDAI FEED Inc - Total Liabilities Trend (2015–2024)

This chart illustrates how HYUNDAI FEED Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 016790 total asset value.

HYUNDAI FEED Inc Competitors by Total Liabilities

The table below lists competitors of HYUNDAI FEED Inc ranked by their total liabilities.

Company Country Total Liabilities
Unic Technology
TWO:5452
Taiwan NT$2.21 Billion
Loxley Public Company Limited
BK:LOXLEY
Thailand ฿6.19 Billion
Globe Union Industrial Corp
TW:9934
Taiwan NT$9.81 Billion
DongWon Development Co.Ltd
KQ:013120
Korea ₩361.51 Billion
Igis Value Plus Reit Co Ltd
KO:334890
Korea ₩146.95 Billion
Hung -Gu Oil Ltd
KQ:024060
Korea ₩14.29 Billion
Kiler Gayrimenkul Yatirim Ortakligi AS
IS:KLGYO
Turkey TL7.91 Billion
Cannara Biotech Inc
V:LOVE
Canada CA$62.63 Million

Liability Composition Analysis (2015–2024)

This chart breaks down HYUNDAI FEED Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of HYUNDAI FEED Inc to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HYUNDAI FEED Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HYUNDAI FEED Inc (2015–2024)

The table below shows the annual total liabilities of HYUNDAI FEED Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩28.05 Billion
≈ $19.01 Million
-84.47%
2023-12-31 ₩180.58 Billion
≈ $122.38 Million
-21.11%
2022-12-31 ₩228.90 Billion
≈ $155.12 Million
+533.27%
2021-12-31 ₩36.15 Billion
≈ $24.50 Million
-7.88%
2020-12-31 ₩39.24 Billion
≈ $26.59 Million
+3.47%
2019-12-31 ₩37.92 Billion
≈ $25.70 Million
+1.87%
2018-12-31 ₩37.23 Billion
≈ $25.23 Million
+3.12%
2017-12-31 ₩36.10 Billion
≈ $24.46 Million
-5.78%
2016-12-31 ₩38.31 Billion
≈ $25.97 Million
-41.07%
2015-12-31 ₩65.02 Billion
≈ $44.06 Million
--

About HYUNDAI FEED Inc

KQ:016790 Korea Packaged Foods
Market Cap
$126.96 Million
₩187.34 Billion KRW
Market Cap Rank
#18387 Global
#819 in Korea
Share Price
₩994.00
Change (1 day)
+0.00%
52-Week Range
₩994.00 - ₩994.00
All Time High
₩15077.70
About

HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more